Lung Cancer

Photofrin Approval Announced for Treatment of Early-Stage Cancer

Published in Cancer Weekly, October 6th, 1997

The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) recommended that the FDA expand its approval of QLT PhotoTherapeutics Inc.'s (QLT) Photofrin (porfimer sodium) for Injection to include early-stage lung cancer.

Specifically, the committee voted in favor of approving Photofrin for the treatment of endobronchial microinvasive non-small cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated.

Besides early-stage lung cancer, QLT's submission also included an application for palliation of advanced disease. The committee however, did not feel that the data presented for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-10-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry